top of page
Macimorelin Therapeutic
Macimorelin as a Potential Therapeutic for Amyotrophic
Lateral Sclerosis (ALS, Lou Gehrig's disease)
Entered Material Transfer Agreement (MTA)
with University
of Queensland
in January 2021
Exclusive rights for AEZS to negotiate a license agreement for the commercial use of the results
University researchers to secure grants and conduct preclinical and clinical studies
AEZS as co-investigator providing medication as well as preclinical and clinical know-how
Investigation as a potential
treatment for Amyotrophic Lateral Sclerosis (ALS,
Lou Gehrig's disease)
Neurodegenerative
motor neuron disease (MND)
with significant unmet medical need
+Our
Pipeline
bottom of page